Skip to main content

Targeting Autophagy in Cancer Therapy: Focus on Small-Molecule Modulators and New Strategies

Cover image for Research Topic "Targeting Autophagy in Cancer Therapy: Focus on Small-Molecule Modulators and New Strategies"
78kviews
Editorial01 February 2023
Editorial: Targeting autophagy in Cancer Therapy: Focus on small-molecule modulators and new strategies

Cancers are one of the deadliest and most difficult to treat diseases in the world. The incidence of tumors in humans is constantly increasing and is one of the main challenges facing the health service. During the last two decades, remarkable advances have been made in diagnosing and developing new drugs to treat cancers through the use of genomics and highthroughput screening. Among them, autophagy plays an important role in tumors. Originally described as the phenomenon of removal and recovery of intracellular waste, autophagy has become a key biological process closely related to many types of cancer, suggesting that autophagy intervention is a promising therapeutic strategy in the development of anti-cancer drugs. Therefore, the discovery of cancer-related targets of autophagy and the related mechanisms of action of targeted small molecule drugs is of paramount importance. Autophagy plays a dynamic role in the inhibition or propagation of a tumor depending on its stage of development. In the early stages of tumor development, autophagy, as a survival and quality control phenomenon, prevents tumor formation. However, when cancers are at an advanced stage, autophagy, as a dynamic degradation and recycling system, contributes to the survival and growth of the tumors and promotes their spread through metastasis.Although the pathology of cancer is fairly well understood, until recently we knew little about its molecular regulation. These mechanisms and their subsequent therapeutic orientation are the subject of our research topic. Of the 10 articles published on our topic, 4 were original studies and 6 were reviews of currently known and emerging therapeutic targets for cancer treatment.Thus, a high-quality database is crucial to elucidate the complicated relationship between autophagy and cancers, elucidate the crosstalk between key autophagy mechanisms and autophagy modulators with their remarkable anticancer activities. To achieve this goal, Fu Therefore, the autophagy pathway is highly drug-sensitive and has multiple drug targets.The inhibition of cytoprotective autophagy in the treatment of cancer is gaining importance as a potentially new therapeutic approach in the treatment of cancer (Zhang et al.). From a clinical perspective, new inhibitors targeting autophagy modulation are currently under investigation and small molecule inhibitors continue to show promise in cancer treatment (Zhang et al.).Review by Wei et al. summarizes the experimental validation and practical application of the strategies using specific and dual inhibitors, drug combinations and antibody-drug conjugates, with the intention of aiding and inspiring future research on nicotinamide phosphoribosyltransferase-targeted oncology drugs. The further development and design of novel, selective, highly efficient, low toxicity and low molecular weight nicotinamide phosphoribosyltransferase inhibitors will not only help basic pathology study, but also bring great hope for the clinical therapy of tumors involving nicotinamide phosphoribosyltransferase to the benefit of more patients (Wei et al.). A promising cancer treatment, which combines sonodynamic therapy with autophagy inhibition using a nanoparticle delivering system, is presented by Zhang et al. Authors speculated that the combination of targeted delivery of sonosensitizer and inhibition of autophagy can effectively kill cancer cells and also avoid the activation of protective-autophagy by increasing the production of reactive oxygen species (Zhang et al.). Autophagy connected genes, miRNAs, lncRNAs, and circRNAs have been described as autophagy biomarkers. As well, developing specially designed drugs for the abovementioned autophagy-associated biomarkers by high-throughput screening, molecular docking, and molecular dynamic simulation may be promising in improving oral squamous cell carcinoma therapy (Gou et al.). Qiang et al. presented that modulating autophagy has been emerging as a promising strategy for colorectal tumor therapy, which can benefit the patients who are not suitable for traditional treatment, and can be used as adjuvant, polypeptides, and small-molecule compounds, photodynamic and non-coding RNAs chemotherapies to overcome drug resistance. New experimental facts, from in vitro and in vivo investigations, suggest a context-dependent anticancer manifestation of autophagy, mediated by an injurious consequence on cancer stem cell survival and metastasis (Troumpoukis et al.). Even though autophagy is a process opposite to apoptosis, evident autophagic influx can in fact trigger apoptosis under certain conditions by activation of caspase 8 and the reduction of endogenous apoptosis inhibitors (Troumpoukis et al.).Taken together, the identification of new drug targets and the development of new treatment strategies based on them offer the exciting prospect of more effective therapies in the treatment of cancers. I thank the authors for their contributions and hope that each article on this research topic will both inform and generate further interest in the effective treatment of tumors.

The author declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

1,575 views

2 citations

ORIGINAL RESEARCH
16 September 2022
Suppression of endoplasmic reticulum stress-dependent autophagy enhances cynaropicrin-induced apoptosis via attenuation of the P62/Keap1/Nrf2 pathways in neuroblastoma
Randong Yang, 9 more and Jian Wang

2,960 views

17 citations

ORIGINAL RESEARCH
24 October 2022
Discovery of novel anti-tumor compounds targeting PARP-1 with induction of autophagy through in silico and in vitro screening
Danfeng Shi, 4 more and Yang Yu

4,317 views

6 citations

MINI REVIEW
12 September 2022
Deconvoluting the complexity of autophagy in colorectal cancer: From crucial pathways to targeted therapies
Liming Qiang, 3 more and Guangfu Jiang

3,280 views

6 citations

Review of various NAMPT inhibitors for the treatment of cancer
REVIEW
7 September 2022
Review of various NAMPT inhibitors for the treatment of cancer
Yichen Wei, 1 more and Wenqiu Zhang
Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in the NAD salvage pathway of mammalian cells and is overexpressed in numerous types of cancers. These include breast cancer, ovarian cancer, prostate cancer, gastric cancer, colorectal cancer, glioma, and b-cell lymphoma. NAMPT is also known to impact the NAD and NADPH pool. Research has demonstrated that NAMPT can be inhibited. NAMPT inhibitors are diverse anticancer medicines with significant anti-tumor efficacy in ex vivo tumor models. A few notable NAMPT specific inhibitors which have been produced include FK866, CHS828, and OT-82. Despite encouraging preclinical evidence of the potential utility of NAMPT inhibitors in cancer models, early clinical trials have yielded only modest results, necessitating the adaptation of additional tactics to boost efficacy. This paper examines a number of cancer treatment methods which target NAMPT, including the usage of individual inhibitors, pharmacological combinations, dual inhibitors, and ADCs, all of which have demonstrated promising experimental or clinical results. We intend to contribute further ideas regarding the usage and development of NAMPT inhibitors in clinical therapy to advance the field of research on this intriguing target.

23,721 views

110 citations

REVIEW
11 August 2022
Inhibiting Cytoprotective Autophagy in Cancer Therapy: An Update on Pharmacological Small-Molecule Compounds
Lijuan Zhang, 3 more and Lu Chen

6,156 views

30 citations

ORIGINAL RESEARCH
9 August 2022
AMTDB: A comprehensive database of autophagic modulators for anti-tumor drug discovery
Jiahui Fu, 6 more and Leilei Fu

2,873 views

4 citations